Vincerx Pharma与Oqory公司合并,开发癌症治疗方法,目标是接近2025年的Q1。 Vincerx Pharma merges with Oqory, Inc., to develop cancer treatments, targeting a Q1 2025 close.

Vincerx Pharma是一家生物制药公司,它签署了一份与Oqory公司合并的具有约束力的期限表,在Vincerx的输油管线上增加了Oqory的第三阶段TROP2抗体药物联合体(ADC)。 Vincerx Pharma, a biopharmaceutical company, has signed a binding term sheet to merge with Oqory, Inc., adding Oqory's Phase 3 TROP2 Antibody-drug Conjugate (ADC) to Vincerx's pipeline. 合并的目的是开发创新的癌症治疗方法。 The merger aims to develop innovative cancer treatments. 财务细节没有披露,但交易须经监管批准,预计到2025年底结束。 Financial details were not disclosed, but the deal is subject to regulatory approvals and is expected to close by the end of Q1 2025.